S&P BSE 200 index opened with a gap-up on Monday, followed by a gap filling but ultimately bounced back to close in green at its peak levels. The index had given a multiple resistance breakout near 4,750 and since then has hit higher high with just one breather in between. 5 BSE 200 stocks hit 52-week high on Monday.

Your behaviour shapes your style of investment. Read on to know more about emotional traps and how to override them.

Godrej Consumer Products reported steady results in Q1FY19. The top line grew in single digits while bottom-line grew strongly.

In terms of volume, tractor volume grew by 39.5 per cent at 24,494 units and construction equipment volume grew by 51.8 per cent to 1,345 units.

Jio has continued its strong subscriber growth trend with net addition during the quarter of 28.7 million (as against 26.5 million in the previous quarter). This is the highest net addition in any quarter since the launch of commercial services.

The company stated that clinical research business will hit top-line from the last quarter of the ongoing financial year. The company is expecting to add a revenue of Rs. 250 crores in the fifth year through clinical research services.

Thyrocare Technologies gained over 7.5 per cent in the early morning trade on Monday as the company announced plans to consider buyback of shares.

The net interest income for the quarter increased by 28 per cent yoy and 9.5 per cent qoq to Rs. 4,381 crore in Q1FY19 vs Rs. 3,405 crore in the same period the previous year. The interest income for the quarter rose by 10.3 per cent yoy to Rs. 11,639 crore in Q1FY19.

Aurobindo Pharma has received the final approval from the US Food and Drug Administration for Bivalirudin Injection indicated for the use as an anticoagulant in patients. The product will be launched in September 2018. With respect to the news, the shares of Aurobindo soared 2 per cent.